Crossmark

Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma

Crossref DOI link: https://doi.org/10.1186/s40364-018-0153-8

Published Online: 2019-01-14

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lundgren, Sebastian

Fagerström-Vahman, Helena

Zhang, Cheng

Ben-Dror, Liv

Mardinoglu, Adil

Uhlen, Mathias

Nodin, Björn

Jirström, Karin http://orcid.org/0000-0003-2257-5000
Funding

Funding for this research was provided by:

Lund University Medical Faculty Foundation (85310)

Vetenskapsrådet (2015-03598)

Fru Berta Kamprads Stiftelse (FBKS-2016-21)
License Information

Text and Data Mining valid from 2019-01-14
More Information

Article History

Received: 5 November 2018

Accepted: 28 December 2018

First Online: 14 January 2019

Ethics approval and consent to participate

: All national and European Union regulations and requirements for handling human samples have been fully complied with during the conduct of this study; i.e. decision no. 1110/94/EC of the European Parliament and of the Council (OJL126 18,5,94), the Helsinki Declaration on ethical principles for medical research involving human subjects, and the European Union Council Convention on human rights and Biomedicine<b>.</b> Approval for the study was obtained from the Ethics committee of Lund University (reference number 530/2008 and 445/07), whereby the committee waived no need for consent other than the option to opt out.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.